Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fourth Quarter Conference Calls, In Brief

Executive Summary

Lipitor in perspective: With $6.45 bil. in annual sales in 2001, Pfizer's Lipitor generates more revenues than the annual Gross Domestic Product of 78 countries, based on calculations of purchasing power parity by the Central Intelligence Agency. If Lipitor meets growth expectations in 2002, it should surpass the GDP of Tajikistan ($7.3 bil.)....Zocor heart protection study: Merck will present data on the effect of Zocor (simvastatin) in the 20,000-patient Heart Protection Study at the American College of Cardiology meeting in March. Preliminary results show that Zocor "reduced the risk of heart attacks and stroke by at least one-third," company says. A filing based on the data is planned for this year...

You may also be interested in...



Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review

Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention

Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review

Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention

Barr Generic Premarin Development Plan Includes Exclusive Supply Deal

Barr anticipates that its exclusive supply agreement with Natural Biologics will permit pricing of its Premarin generic as a single-source generic

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel